Single-molecule PCR analysis of germ line mutation induction by anticancer drugs in mice

• Published in: Cancer research (Chicago, Ill.) Ill.), 2008-05, Vol.68 (10), p.3630-3636
• Main Authors: Glen, Colin D, Smith, Andrew G, Dubrova, Yuri E
• Format: Article
• Language: English
• Subjects: Animals; Antineoplastic Agents - pharmacology; Bleomycin - pharmacology; Cyclophosphamide - pharmacology; DNA Mutational Analysis; Dose-Response Relationship, Drug; Germ-Line Mutation; Male; Mice; Mice, Inbred C57BL; Mice, Inbred CBA; Mitomycin - pharmacology; Neoplasms - chemically induced; Neoplasms - drug therapy; Neoplasms - genetics; Polymerase Chain Reaction - methods; Procarbazine - pharmacology
• ISSN: 0008-5472; 1538-7445
• DOI: 10.1158/0008-5472.CAN-08-0484

Understanding and estimating the genetic hazards of exposure to chemical mutagens and anticancer drugs in humans requires the development of efficient systems for monitoring germ line mutation. The suitability of a single-molecule PCR-based approach for monitoring mutation induction at the mouse expanded simple tandem repeat (ESTR) locus Ms6-hm by chemical mutagens and anticancer drugs has been validated. The frequency of ESTR mutation was evaluated in the germ line of male mice exposed to the well-characterized alkylating agent and mutagen, ethylnitrosourea, and four widely used anticancer drugs, bleomycin, cyclophosphamide, mitomycin C, and procarbazine. The dose-response of ethylnitrosourea-induced mutation was found to be very close to that previously established using a pedigree-based approach for ESTR mutation detection. Paternal exposure to the clinically relevant doses of bleomycin (15-30 mg/kg), cyclophosphamide (40-80 mg/kg), and mitomycin C (2.5-5 mg/kg) led to statistically significant, dose-dependent increases in ESTR mutation frequencies in the germ line of treated male mice. Exposure to procarbazine led to a maximal increase in mutation frequency at 50 mg/kg, with a plateau at the higher concentrations. The results of this study show that the single-molecule PCR technique provides a new and efficient experimental system for monitoring the genetic effects of anticancer drugs, capable of detecting increases in mutation rates at clinically relevant doses of exposure. In addition, this approach dramatically reduces the number of mice needed for the measurement of germ line mutation induction.